CA2364637A1 - Proteines humaines secretees (50) - Google Patents
Proteines humaines secretees (50) Download PDFInfo
- Publication number
- CA2364637A1 CA2364637A1 CA002364637A CA2364637A CA2364637A1 CA 2364637 A1 CA2364637 A1 CA 2364637A1 CA 002364637 A CA002364637 A CA 002364637A CA 2364637 A CA2364637 A CA 2364637A CA 2364637 A1 CA2364637 A1 CA 2364637A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- human
- sequence
- polypeptide
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Cette invention concerne 50 nouvelles protéines humaines sécrétées et des acides nucléiques isolés renfermant des régions de codage des gènes codant pour de telles protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et des méthodes recombinantes permettant de produire des protéines humaines sécrétées. De plus, l'invention s'intéresse é des méthodes diagnostiques et thérapeutiques utiles pour le diagnostic et le traitement de troubles en rapport avec ces nouvelles protéines humaines sécrétées.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12414399P | 1999-03-12 | 1999-03-12 | |
US60/124,143 | 1999-03-12 | ||
US16866399P | 1999-12-03 | 1999-12-03 | |
US60/168,663 | 1999-12-03 | ||
PCT/US2000/006042 WO2000055200A1 (fr) | 1999-03-12 | 2000-03-09 | Proteines humaines secretees (50) |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2364637A1 true CA2364637A1 (fr) | 2000-09-21 |
Family
ID=26822248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002364637A Abandoned CA2364637A1 (fr) | 1999-03-12 | 2000-03-09 | Proteines humaines secretees (50) |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1161447A1 (fr) |
JP (1) | JP2003508013A (fr) |
AU (1) | AU3518000A (fr) |
CA (1) | CA2364637A1 (fr) |
WO (1) | WO2000055200A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002224122A1 (en) * | 2000-11-29 | 2002-06-11 | Takeda Chemical Industries Ltd. | Method of screening remedy for diabetes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
-
2000
- 2000-03-09 EP EP00913809A patent/EP1161447A1/fr not_active Withdrawn
- 2000-03-09 JP JP2000605626A patent/JP2003508013A/ja not_active Withdrawn
- 2000-03-09 WO PCT/US2000/006042 patent/WO2000055200A1/fr not_active Application Discontinuation
- 2000-03-09 AU AU35180/00A patent/AU3518000A/en not_active Abandoned
- 2000-03-09 CA CA002364637A patent/CA2364637A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1161447A1 (fr) | 2001-12-12 |
JP2003508013A (ja) | 2003-03-04 |
AU3518000A (en) | 2000-10-04 |
WO2000055200A1 (fr) | 2000-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2368068A1 (fr) | 27 proteines humaines secretees | |
CA2382185A1 (fr) | 48 proteines secretees humaines | |
CA2383041A1 (fr) | 49 proteines secretees humaines | |
CA2370489A1 (fr) | 49 proteines humaines secretees | |
CA2364209A1 (fr) | 49 proteines secretees humaines | |
CA2365223A1 (fr) | Proteines humaines secretees (46) | |
CA2368281A1 (fr) | 50 proteines humaines secretees | |
CA2370767A1 (fr) | 49 proteines humaines secretees | |
CA2368467A1 (fr) | 50 proteines humaines secretees | |
CA2391364A1 (fr) | 47 proteines humaines secretees | |
CA2364635A1 (fr) | 47 proteines humaines secretees | |
CA2365522A1 (fr) | 48 proteines secretees humaines | |
CA2368302A1 (fr) | 49 proteines secretees par un etre humain | |
CA2370441A1 (fr) | 50 proteines humaines secretees | |
CA2391361A1 (fr) | 47 proteines secretees humaines | |
CA2390946A1 (fr) | 49 proteines secretees humaines | |
CA2364650A1 (fr) | Proteines humaines secretees (50) | |
CA2365247A1 (fr) | Proteines humaines secretees (49) | |
CA2371172A1 (fr) | 50 proteines humaines secretees | |
CA2368210A1 (fr) | Cinquante proteines humaines secretees | |
CA2368916A1 (fr) | 49 proteines humaines secretees | |
CA2368442A1 (fr) | 48 proteines humaines secretees | |
CA2367620A1 (fr) | Proteines humaines secretees (47) | |
CA2368700A1 (fr) | Quarante-neuf proteines humaines secretees | |
CA2382769A1 (fr) | 42 proteines humaines secretees |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |